Zealand Pharma Announces Financial Results for the First Nine Months of 2022
Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the interim report for the three and nine months ended September 30, 2022 and provided a corporate update
By Zealand Pharma
Published - Nov 10, 2022, 09:04 AM ET
Last Updated - Mar 27, 2024, 10:42 AM EDT
Company announcement No. 51 / 2022
Zealand Pharma Announces Financial Results for the First Nine Months of 2022
Copenhagen, Denmark November 10, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the interim report for the three and nine months ended September 30, 2022 and provided a corporate update.
Key strategic objectives achieved